Featured News

May 15, 2018

The pharmaceutical research company Roots Analysis talks to CEO Brian Frenzel about Tosk’s promising kRAS program.

Roots Analysis: We are aware that Tosk is focused on the development of discovery stage drug candidates targeting KRAS mutations. Can you provide some insights on […]